Biologics Manufacturing: Asia vs Europe - Opportunity, Risk, And The Shifting Supply Base

The global distribution of biologics manufacturing capacity is changing substantially. Production, historically centered in North America and Europe, is increasingly expanding across Asia, prompting reassessment of manufacturing location strategies for critical biologic therapies.

Comparisons between European and Asian manufacturing hubs are shaped by multiple variables beyond cost, including scalability, development and commercial timelines, regulatory alignment, intellectual property protection, and exposure to geopolitical risk. These factors influence sourcing decisions differently across early development, clinical manufacturing, and commercial supply.

Asian manufacturing organizations have become integral to large‑scale, cost‑efficient production, particularly for biosimilars and programs with tight margin constraints. In contrast, European facilities continue to provide strengths in early‑phase development, regulatory rigor, technical oversight, and geographic proximity to key markets. Increasingly, companies are adopting diversified manufacturing strategies to balance efficiency with resilience, mitigating risks associated with capacity limitations, regulatory complexity, and political uncertainty across global supply networks.